Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | POLG | P54098 | 1/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 12/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17617326 | 1.00 | POLB (0.57) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17622435 | 0.98 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17621845 | 0.98 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17621846 | 0.98 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17622434 | 0.98 | POLB (0.55) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL23783761 | 0.95 | POLB (0.52) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL24383682 | 0.93 | POLB (0.51) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17622565 | 0.92 | POLB (0.60) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL23346501 | 0.92 | POLB (0.60) | POLBPOLA1POLGHPRT1MEN1 | |
| SCHEMBL17617647 | 0.92 | POLB (0.60) | POLBPOLA1POLGHPRT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572377-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220395510-A1 | Nucleotide Analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OFFICE OF THE GENERAL COUNSEL (024) | 2022-12-15 | — | — | US | disclosed |
| US-11344555-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220072004-A1 | Nucleotide Analogs | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-03-10 | — | — | US | disclosed |
| EP-3350191-B9 | NUCLEOTIDE ANALOGS | UNIV CALIFORNIA (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3875462-A1 | NUCLEOTIDE ANALOGS | The Regents of The University of California (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210246153-A1 | Nucleotide Analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-08-12 | — | — | US | disclosed |
| US-11014950-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3350191-B1 | NUCLEOTIDE ANALOGS | UNIV CALIFORNIA (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200316076-A1 | Nucleotide Analogs | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-10-08 | — | — | US | disclosed |
| US-9493493-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493493-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2016-03-24 | — | — | US | disclosed |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2016-03-24 | — | — | US | disclosed |
| WO-2016044281-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-24 | — | — | WO | disclosed |
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572377-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20200316076-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-11014950-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885POLA1 350/4885POLG 524/4885 |
| US-20220395510-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20220072004-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-11344555-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20210246153-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885POLA1 350/4885POLG 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.